These findings align with our pilot study26 in insulin-treated patients with diabetes and cognitive impairment, which showed significantly lower mortality in CGM users (adjusted odds ratio, 0.20; 95% CI, 0.10-0.60) and with the study by Reaven et al,49 reporting 14% (T2D) and 57% (T1D) lower mortality in CGM users. This evidence concerns the gene INS and diabetes mellitus.